title: Juvenile xanthogranuloma with hematological dysfunction treated with 2CDA-AraC.
abstract: Juvenile xanthogranuloma was diagnosed in two infants aged 8 and 2 months with skin lesions, hepatosplenomegaly, and pancytopenia. Disease control was not achieved with first-line vinblastine-steroid-VP16 combination therapy. Two courses of 2-chlorodeoxyadenosine (2CDA) (0.3 mg/kg) and cytosine arabinoside (AraC) (1 g/m(2)) were then administered for 5 days and were followed, after hematological recovery, by maintenance therapy. Both patients had normal complete blood cell counts and no signs of JXG, respectively, 31 and 24 months after diagnosis.
authors.affiliation: Département de Pédiatrie, Unité d'Hémato Oncologie, CHU Tours, Tours, France. p.blouin@chu-tours.fr
authors.forename: Pascale
authors.initials: P
authors.lastname: Blouin
authors.forename: Marion
authors.initials: M
authors.lastname: Yvert
authors.forename: Flavie
authors.initials: F
authors.lastname: Arbion
authors.forename: Anne
authors.initials: A
authors.lastname: Pagnier
authors.forename: Jean François
authors.initials: JF
authors.lastname: Emile
authors.forename: Laurence
authors.initials: L
authors.lastname: Eitenschenck
authors.forename: Marie-Christine
authors.initials: MC
authors.lastname: Machet
authors.forename: Dominique
authors.initials: D
authors.lastname: Plantaz
authors.forename: Philippe
authors.initials: P
authors.lastname: Colombat
authors.forename: Corinne Armari
authors.initials: CA
authors.lastname: Alla
authors.forename: Jean
authors.initials: J
authors.lastname: Donadieu
mesh_terms: D017338:Cladribine / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D006402:Hematologic Diseases / Q000209:etiology*; D006801:Humans; D007223:Infant; D008297:Male; D014972:Xanthogranuloma, Juvenile / Q000097:blood / Q000188:drug therapy*
chemical_list: D003561:Cytarabine; D017338:Cladribine